Managing hCG Monotherapy: The Guide That Should Exist

In 2026, a dataset of 9,079 men on hCG revealed something striking: only 392 — just 4.3% — were using it as monotherapy. The rest received hCG as an adjunct, typically alongside testosterone replacement. This ratio captures the central paradox of hCG in male hypogonadism. It is the only treatment that simultaneously raises testosterone, preserves fertility, maintains testicular volume, and carries lower polycythemia risk than exogenous testosterone. And almost nobody prescribes it as a primary treatment.

The reason isn't efficacy. It's knowledge. Most endocrinologists learn hCG as a fertility drug. Most urologists reach for TRT first. The practical knowledge needed to manage hCG monotherapy — how to dose it, when to check labs, how to handle estradiol, what to do when supply runs out — exists scattered across a handful of studies, none of which were designed to create a management protocol.

This article assembles that scattered evidence into what it should have been from the start: a practical guide.

Who Should Consider hCG Monotherapy

hCG is not TRT. It does not replace the end product — it mimics the signal. Human chorionic gonadotropin binds the same receptor as luteinizing hormone on Leydig cells, stimulating endogenous testosterone production while maintaining intratesticular testosterone concentrations. This distinction matters for specific patient populations.

The strongest case for hCG monotherapy exists in men with secondary hypogonadism who want to preserve fertility. The AUA/ASRM 2024 guidelines are explicit: exogenous testosterone should not be prescribed to men currently trying to conceive. hCG preserves and often improves spermatogenesis — 70% of men achieve sperm production on hCG alone, rising to 86% with added FSH.

Beyond fertility, hCG monotherapy suits men with polycythemia concerns (hCG carries lower erythrocytosis risk than exogenous testosterone), men who want to maintain testicular volume (TRT causes measurable atrophy), and younger men who want to avoid permanent HPG axis suppression. It also serves as a bridge for men transitioning off TRT or anabolic steroids who need gonadal stimulation while their pituitary recovers.

The key mechanistic distinction: hCG bypasses the hypothalamus and pituitary entirely. This means it works even when the pituitary is damaged — unlike SERMs like enclomiphene, which require functional gonadotrophs. For organic secondary hypogonadism (tumor, radiation, infiltrative disease), hCG is the logical choice if TRT is undesirable.

The Dosing Pattern Discovery That Changed Everything

In 1984, a Dutch endocrinology team led by Anton Smals published a study in the Journal of Clinical Endocrinology and Metabolism that should have reshaped hCG prescribing. It didn't — because almost nobody read it.

Smals compared two approaches delivering the same total weekly dose of 1,500 IU: a single bolus injection versus five daily divided doses of 300 IU. The results were dramatic.

The single bolus produced a sharp testosterone peak followed by a crash below baseline. The estradiol spike triggered steroidogenic enzyme downregulation — the very desensitization that gives hCG a bad name. The divided dosing produced nearly twice the testosterone exposure over the same period, with no estradiol spike and no desensitization.

The lesson: how you deliver hCG matters more than total dose. A 1984 paper with 40 years of replication opportunity. And yet, the most common prescribing pattern remains large bolus injections two or three times per week.

Practical Dosing Protocols

No head-to-head dosing frequency comparison trial exists. This is one of the most basic questions in hCG management, and the medical establishment has not answered it. What follows is synthesized from the available evidence across multiple studies:

The FDA-approved label for hypogonadism suggests 4,000 IU IM three times weekly — a dose most clinicians now consider supraphysiologic. Real-world practice has settled on lower doses. Akhras et al. (2022) reported a mean dose of approximately 1,500 IU with good outcomes over a mean follow-up of 41.7 weeks.

Subcutaneous vs Intramuscular: A Settled Question

Saal et al. demonstrated in 1991 that subcutaneous and intramuscular hCG injection produce identical hormonal responses. Subcutaneous has a slightly delayed peak and prolonged half-life compared to intramuscular, but testosterone, LH, and FSH responses are equivalent. A 1994 study in men with isolated hypogonadotropic hypogonadism confirmed comparable testosterone levels with self-administered subcutaneous injections.

The practical implications are significant. Subcutaneous injection uses smaller needles (25–28 gauge, 0.5-inch), can be administered in the abdomen or thigh, requires no medical training, and is strongly preferred by patients. There is no clinical reason to inject hCG intramuscularly.

The Estradiol Problem — and How to Manage It

hCG stimulates testicular aromatase directly. Unlike exogenous testosterone, where estradiol comes primarily from peripheral aromatization in adipose tissue, hCG-driven estradiol is produced locally within the testes. This means estradiol rises alongside testosterone — sometimes disproportionately.

The Smals data explains why: bolus dosing causes an estradiol spike that triggers steroidogenic enzyme downregulation. Divided dosing avoids this. But even with optimal dosing, some men will need estradiol management.

Recombinant vs Urinary: Clinically Interchangeable

Handelsman et al. published the first direct comparison in men in 2024 (Clinical Endocrinology). While pharmacokinetic profiles were not formally bioequivalent, pharmacodynamic effects — the actual testosterone, DHT, and estradiol responses — were equivalent. No difference in testosterone time course (p=0.69), DHT (p=0.42), or estradiol (p=0.38). The recommended recombinant hCG starting dose for men is 62.5 µg (approximately 6 clicks of the Ovidrel pen).

Both products are clinically interchangeable. The practical difference is supply: recombinant hCG (Ovidrel) has been more consistently available during the ongoing 2026 shortage. One caveat: recombinant hCG is produced from Chinese hamster ovary cells and is contraindicated in individuals with hamster protein allergy — a rare but real consideration.

What the Evidence Shows: Outcomes

The outcomes data for hCG monotherapy is thin but consistently positive. This is not because hCG doesn't work — it's because almost nobody has studied it as a primary treatment seriously enough to generate the data.

The safety signal is reassuring: across all available studies, hCG monotherapy has produced zero thromboembolic events, no significant changes in hematocrit, PSA, or HbA1c. This doesn't mean hCG is without risk — hypersensitivity reactions including anaphylaxis are possible — but the cardiovascular and hematological profile is clean.

hCG vs Enclomiphene: Different Tools, Different Targets

The most common question from patients exploring alternatives to TRT: should I use hCG or enclomiphene? The answer depends on anatomy.

Enclomiphene blocks estrogen feedback at the pituitary, amplifying LH and FSH secretion. It only works if the pituitary can respond. For functional hypogonadism — obesity, opioids, stress — either treatment is viable. For organic secondary hypogonadism — pituitary tumor, radiation damage, Kallmann syndrome — enclomiphene may fail. hCG works regardless.

Habous et al. (2018, n=282) compared CC 50 mg daily, hCG 5,000 IU twice weekly, and the combination over 12 weeks. All three arms raised testosterone comparably. The SERM arm achieved slightly higher testosterone (158 vs 134 ng/dL increase, p<0.002), but the combination produced the best symptom scores (qADAM 15.13 vs 12.73 CC vs 11.82 hCG, p<0.01). The ICSM 2024 consensus recommends enclomiphene over racemic clomiphene when available, and hCG for hypogonadism with infertility.

hCG's unique advantages: it maintains intratesticular testosterone (critical for spermatogenesis), carries lower polycythemia risk, and works independent of pituitary function. Its disadvantages: it requires injection, costs more, and is subject to ongoing supply constraints.

Monitoring: A Practical Timeline

No published hCG monotherapy monitoring protocol exists. This timeline is synthesized from endocrinology society guidelines, study protocols, and clinical practice patterns:

The Access Crisis

In March 2020, the FDA reclassified hCG under the Biologics Price Competition and Innovation Act, immediately shutting down compounding pharmacies that had been producing affordable hCG for men. By 2023, only 5 of 75 FDA-registered 503b outsourcing facilities still provided hCG — 6.67%. The supply never recovered.

In 2026, the landscape remains constrained:

Most insurance plans exclude hCG for male hypogonadism, leaving patients to pay out of pocket. GoodRx coupons can reduce costs by 20–60%. The Drug Shortage Compounding Patient Access Act (H.R. 5316), introduced in September 2025, could restore compounding access if passed — but it has not become law.

The regulatory irony is bitter: the FDA's 2020 reclassification was designed to improve safety standards for biologics. In practice, it priced thousands of men out of the only treatment that preserves their fertility while addressing their hypogonadism. Meanwhile, testosterone — which shuts down spermatogenesis and is classified as a Schedule III controlled substance — remains widely available and covered by insurance.

Self-Administration: Practical Details

For men self-administering hCG at home:

Storage: Room temperature before reconstitution. After reconstitution with bacteriostatic water, refrigerate and use within 60–90 days.

Reconstitution: Gently swirl — never shake. Draw bacteriostatic water into vial, let powder dissolve completely.

Injection: 25–28 gauge needle, 0.5-inch length. Subcutaneous into abdomen, thigh, or upper arm. 45-degree angle. Rotate injection sites.

Timing: Consistent schedule matters more than time of day. If dosing 3×/week, space evenly (e.g., Mon/Wed/Fri).

The TRT Comparison — Post-TRAVERSE

The cardiovascular question that long shadowed testosterone therapy has been largely resolved. The TRAVERSE trial (n=5,246, mean 33 months) demonstrated non-inferiority for major adverse cardiovascular events (HR 0.96). The FDA removed its cardiovascular black box warning from all testosterone products in February 2025. An expert panel in December 2025 discussed further liberalization, including removing prostate cancer contraindications and Schedule III classification.

TRT is now considered cardiovascularly safe. This changes the calculus for hCG. The argument is no longer "hCG is safer than TRT" — it's that hCG offers qualitatively different benefits: fertility preservation, maintained intratesticular hormone milieu, lower polycythemia risk, and no exogenous hormone dependency. For the right patient, these advantages matter regardless of TRT's cardiovascular profile.

One finding deserves mention: the TRAVERSE fracture subtrial (NEJM, January 2024) found testosterone gel was associated with more fractures (HR 1.43, p=0.03) — likely due to increased physical activity causing more falls, not bone damage. Whether this applies to hCG is unknown, but hCG's maintenance of local estradiol production within the testes may be bone-protective.

What We Still Don't Know

The evidence gaps in hCG monotherapy are not oversights — they are the defining feature of this treatment's neglect by the medical establishment. These basic questions remain unanswered:

These are not niche research questions. They are the basics that any standard treatment would have answered decades ago. That they remain unanswered for hCG — a drug approved for hypogonadism since the 1970s — reflects a systematic deprioritization by the medical establishment. TRT is simpler, more profitable, and better understood. hCG monotherapy fell through the gap.

The Bottom Line

hCG monotherapy is the right treatment for a specific population: men with secondary hypogonadism who want preserved fertility, lower polycythemia risk, maintained testicular function, and physiologic intratesticular hormone production. The evidence that exists is consistently positive. The safety profile is clean. The Smals dosing data from 1984 tells you exactly how to optimize it.

What's missing is not proof that hCG works. What's missing is the infrastructure of knowledge that every primary treatment deserves — the dose-response curves, the long-term outcomes, the head-to-head comparisons, the monitoring protocols validated by prospective trials. Until those studies happen, clinicians and patients are left to synthesize management protocols from scattered evidence.

That synthesis is what this article represents. It shouldn't have to exist as a blog post. It should be in every endocrinology textbook.

---

Key Sources

Smals AGH et al. "Differential effect of single high dose and divided small dose administration of human chorionic gonadotropin on Leydig cell steroidogenic desensitization." JCEM, 1984. PMID: 6693540
Coviello AD et al. "Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men." JCEM, 2005
Akhras S et al. "The Use of Human Chorionic Gonadotropin Monotherapy for Hypogonadism." Cureus, 2022
Habous M et al. "Clomiphene citrate and human chorionic gonadotropin are both effective in restoring testosterone in hypogonadism." BJU Int, 2018
Handelsman DJ et al. "Pharmacokinetics and pharmacodynamics of recombinant vs urinary hCG in men." Clin Endocrinol, 2024. PMID: 38446525
Saal W et al. "Pharmacodynamics of SC vs IM hCG in healthy males." Fertil Steril, 1991
Liu PY et al. "The effects of recombinant hCG on body composition in older men." JCEM, 2002
Zhang X et al. "Body composition in CHH men treated with gonadotropins." Clin Endocrinol, 2025
Stocks SJ et al. "Gonadotropin combination for spermatogenesis recovery." Fertil Steril, 2024
Clift A, Morgentaler A. "Real-world hCG prescribing patterns in 9,079 men." WJMH, 2026
Khera M et al. "ICSM 2024 consensus on SERMs and hCG in hypogonadism." Sex Med Rev, 2025
AUA/ASRM 2024 Guidelines on Male Infertility
Barber JL et al. "Availability of compounded hCG after FDA biologics reclassification." Sexual Medicine, 2023
İbis HB et al. "Post-AAS fertility recovery with CC+hCG." BJU Int, 2026
TRAVERSE Trial. NEJM, 2023; Fracture subtrial, NEJM, 2024